|Bid||2.5940 x N/A|
|Ask||2.8580 x N/A|
|Day's Range||2.7900 - 2.7900|
|52 Week Range||2.3480 - 17.0452|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, CANADA / ACCESSWIRE / June 22, 2020 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company") today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201.
“Cannabis stores and cannabis producers” are on Ontario’s list of workplaces. It’s a win for a sector that was facing tough times long before COVID-19 threatened the global economy.